Norman E. ‘Ned’ Sharpless became director of the US National Cancer Institute (NCI) in 2017. From April 2019, he served as acting commissioner of the US Food and Drug Administration (FDA), and he returned to the NCI in November. Douglas R. Lowy has been the principal deputy director of the NCI since 2010, having also served as acting director twice, most recently in 2019. Nature Cancer spoke with both last fall to learn more about what makes NCI and its leadership tick.

中文翻译：

---

在 NCI 塑造癌症研究的未来

Norman E. 'Ned' Sharpless 于 2017 年成为美国国家癌症研究所 (NCI) 主任。从 2019 年 4 月起，他担任美国食品和药物管理局 (FDA) 代理专员，并于 11 月返回 NCI。Douglas R. Lowy 自 2010 年以来一直担任 NCI 的首席副主任，还曾两次担任代理主任，最近一次是在 2019 年。 Nature Cancer 去年秋天与两人进行了交谈，以了解更多关于 NCI 及其领导层的原因。